CDMO News
Hongene Biotech’s Integrated CDMO Services Advance GalNAc-Conjugated siRNA to Clinical Stage
Hongene Biotech Corporation, a contract development and manufacturing organisation (CDMO) focused on nucleic acid therapeutics, has played a central role in progressing DNV001, a novel GalNAc-conjugated siRNA therapy developed by Hangzhou Dingle Xinwei Biotechnology. The investigational new drug (IND) application
10 July 2025